Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 7, 2015, Pages 2133-2143

  Tumbarello, Mario ^a   Trecarichi, Enrico Maria ^a   De Rosa, Francesco Giuseppe ^b,c   Giannella, Maddalena ^d   Giacobbe, Daniele Roberto ^e   Bassetti, Matteo ^f   Losito, Angela Raffaella ^a   Bartoletti, Michele ^d   Del Bono, Valerio ^e   Corcione, Silvia ^b,c   Maiuro, Giuseppe ^a   Tedeschi, Sara ^d   Celani, Luigi ^a   Cardellino, Chiara Simona ^b,c   Spanu, Teresa ^a   Marchese, Anna ^e   Ambretti, Simone ^d   Cauda, Roberto ^a   Viscoli, Claudio ^e   Viale, Pierluigi ^d  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c AMEDEO DI SAVOIA HOSPITAL   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f S Maria Hospital   (Italy)

Author keywords

Carbapenem resistance; Carbapenemases; Colistin resistance; Combination therapy; Inadequate empirical therapy; Meropenem MICs; Treatment

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; ERTAPENEM; GENTAMICIN; MEROPENEM; RIFAMPICIN; TIGECYCLINE;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; APACHE; ARTICLE; BLOODSTREAM INFECTION; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; FEMALE; HUMAN; IN VITRO STUDY; ITALY; KLEBSIELLA PNEUMONIAE CARBAPENEMASE PRODUCING KLEBSIELLA PNEUMONIAE INFECTION; KLEBSIELLA PNEUMONIAE INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL RATE; TEACHING HOSPITAL; URINARY TRACT INFECTION;

EID: 84936929460     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv086     Document Type: Article

References (35)

1. Nordmann P, Naas T, Poirel L. Global spread of carbapenemaseproducing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8.
2. Grundmann H, Livermore DM, Giske CG et al. Carbapenem-nonsusceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010; 15: pii=19711.
3. Cantón R, Akóva M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18: 413-31.
4. Akova M, Daikos GL, Tzouvelekis L et al. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012; 18: 439-48.
5. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-50.
6. Gupta N, Limbago BM, Patel JB et al. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53: 60-7.
7. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 2012; 11: 32.
8. Hirsch EB, TamVH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65: 1119-25.
9. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135-41.
10. Munoz-Price LS, Poirel L, Bonomo RA et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: 785-96.
11. Giannella M, Trecarichi EM, De Rosa FG et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clin Microbiol Infect 2014; 20: 1357-62.
12. Tumbarello M, Trecarichi EM, Tumietto F et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58: 3514-20.
13. Sbrana F, Malacarne P, Viaggi B et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae in intensive care unit. Clin Infect Dis 2013; 56: 697-700.
14. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56: 2108-13.
15. Daikos GL, Tsaousi S, Tzouvelekis LS et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58: 2322-8.
16. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-713.
17. Rodríguez-Baño J, Picón E, Gijón P et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrumb-lactamase-producing Escherichia coli. J ClinMicrobiol 2010; 48: 1726-31.
18. Garner JS, Jarvis WR, Emori TG et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
19. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 5.0, Valid from 2015-01-01. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_5.0_Breakpoint_Table_01.pdf.
20. KPCcontaining Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 2009; 63: 427-37.
21. Dellinger RP, Levy MM, Rhodes A et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013; 39: 165-228.
22. ECDC. Annual Epidemiological Report on Communicable Diseases in Europe 2008. Stockholm: ECDC, 2008; 16-38. http://ecdc.europa.eu/en/publications/Publications/0812_SUR_Annual_Epidemiological_Report_2008.pdf.
23. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic co-morbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-83.
24. Knaus WA, Wagner DP, Draper EA et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-36.
25. Patel G, Huprikar S, Factor SH et al. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-106.
26. Viale P, Giannella M, Lewis R et al. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11: 1053-63.
27. Zarkotou O, Pournaras S, Tselioti P et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17: 1798-803.
28. FalagasME, Lourida P, Poulikakos P et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58: 654-63.
29. Tzouvelekis LS, Markogiannakis A, Piperaki E et al. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2014; 20: 862-72.
30. Wiskirchen DE, Koomanachai P, Nicasio AM et al. In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011; 55: 1420-7.
31. Hirsch EB, Guo B, Chang KTet al. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis 2013; 207: 786-93.
32. Elemam A, Rahimian J, Doymaz M. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol 2010; 48: 3558-62.
33. Pournaras S, Vrioni G, Neou E et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011; 37: 244-7.
34. Capone A, Giannella M, Fortini D et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19: 23-30.
35. Dubrovskaya Y, Chen TY, Scipione MR et al. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother 2013; 57: 5394-7.